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Clinical ResearchValidity of Estimated Glomerular Filtration
Rates for Assessment of Renal Function
After Renal Artery Stenting in Patients With
Atherosclerotic Renal Artery StenosisGeoffrey M. Crimmins, MD, Ryan D. Madder, MD, Victor Marinescu, MD,
Robert D. Saﬁan, MD
Royal Oak, MichiganObjectives The purpose of this study was to evaluate the validity of estimates of glomerular ﬁltration
rate (eGFR) for assessing serial changes in renal function after renal artery stenting.
Background eGFR are unreliable for assessing serial renal function in patients with atherosclerotic
renal artery stenosis (RAS). eGFR have not been validated for assessment of serial renal function after
renal artery stenting.
Methods Serum creatinine (SCr) and 125I-iothalamate GFR (iGFR) were measured in RAS patients
before and after renal artery stenting. eGFR were calculated from Modiﬁcation of Diet in Renal Disease
(MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Cockcroft-Gault (CG)
formulas. Using iGFR as the reference standard, the sensitivity, speciﬁcity, and area under the receiver-
operating characteristic curve (AUC) were determined for MDRD, CKD-EPI, and CG for assessing
changes in GFR before and after intervention.
Results Between 1998 and 2007, 84 patients underwent iGFR and eGFR before and after renal artery
stenting. All eGFR demonstrated poor sensitivity and reliability for detecting 20% changes in iGFR,
and poor agreement in the magnitude and direction of change in iGFR, before and after renal stenting.
Conclusions In RAS patients, eGFR demonstrate poor sensitivity and reliability for detecting
meaningful changes in iGFR after renal artery stenting. eGFR should be abandoned as primary
endpoints in major clinical trials assessing the impact of renal revascularization on renal function.
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Table 1. Baseline Characteristics (N ¼ 84)
Age, yrs 69.4  8.8
Male 44 (52.4)
African American 2 (2.4)
Weight, kg 77.4  16.0
Height, m 1.68  11.0
Hypertension 83 (98.8)
Diabetes mellitus 25 (29.8)
Unilateral RAS 62 (73.8)
Bilateral RAS 22 (26.2)
SCr, mg/dl 1.5  0.71
iGFR, ml/min/1.73 m2 53.5 (39.2–65.3)
CG GFR, ml/min/1.73 m2 48.6 (41.2–63.2)
MDRD GFR, ml/min/1.73 m2 49.8 (37.2–65.6)
CKD-EPI GFR, ml/min/1.73 m2 48.0 (34.7–64.4)
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544Atherosclerotic renal artery stenosis (RAS) is highly preva-
lent among elderly patients with hypertension, chronic
kidney disease (CKD), and coronary and peripheral arterial
disease. Although renal artery revascularization is most often
performed by stenting, several recent randomized trials re-
ported no improvement in renal function with stenting
compared with medical therapy (1–3), based on estimates of
glomerular ﬁltration rates (eGFR) to assess serial renal func-
tion. However, a recent study demonstrated that compared
with measured glomerular ﬁltration rate (GFR), eGFR have
poor sensitivity and reliability for detecting 20% changes in
measured GFR, and recommended that eGFR not be used to
assess serial GFR in patients with RAS (4). The purpose of
this study is to evaluate the validity of eGFR for assessing
serial changes in renal function after renal artery stenting.Values are mean  SD, n (%), or median (interquartile range).
CG ¼ Cockcroft-Gault; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration;
GFR ¼ glomerular ﬁltration rate; iGFR ¼ 125I-iothalamate glomerular ﬁltration rate;
MDRD ¼ Modiﬁcation of Diet in Renal Disease; RAS ¼ atherosclerotic renal artery stenosis;
SCr ¼ serum creatinine.
Abbreviations
and Acronyms
AUC = area under the
receiver-operating
characteristic curve
CG = Cockcroft-Gault
CI = conﬁdence interval
CKD = chronic kidney
disease
CKD-EPI = Chronic Kidney
Disease Epidemiology
Collaboration
eGFR = estimated glomerular
ﬁltration rate
iGFR = 125I-iothalamate
glomerular ﬁltration rate
MDRD = Modiﬁcation of Diet
in Renal Disease
RAS = atherosclerotic renal
artery stenosis
SCr = serum creatinineMethods
Patient selection and GFR
assessment. Between 1998 and
2007, serial 125I-iothalamate glo-
merular ﬁltration rates (iGFR)
were measured in 254 patients
with RAS, as previously des-
cribed (4). Within this popula-
tion, 81 patients underwent
renal artery stenting and are
the focus of the present study.
Criteria for renal revasculariza-
tion were previously deﬁned (5).
Brieﬂy, these criteria included
those patients with unilateral or
bilateral RAS 70% and clinical
evidence for hypertensive crisis
associated with nonischemic pul-
monary edema or acute neuro-
logical injury; patients with severe
hypertension alone, known renalTable 2. Assessment of GFR Before and After Renal Artery Stenting
GFR Method
GFR Before Stenting
(ml/min/1.73 m2)
GFR After Stenting
(ml/min/1.73 m2)
iGFR 54  19.9 56.2  24.3
MDRD 51.4  20.2 51.6  23.7
CKD-EPI 49.4  19.8 48.9  21.3
CG 63.2  20.7 64.2  13.4
Values are mean  SD. p ¼ NS for all measures before and after stenting.
Abbreviations as in Table 1.parenchymal disease, proteinuria 1.0 g in 24 h, or antici-
pated life expectancy 2 years were excluded. GFR was
measured by the plasma disappearance of iGFR using a
2-compartment pharmacokinetic model (6), as detailed pre-
viously (4). Brieﬂy, blood samples were drawn 5, 10, and
15 min after administration of 0.15 ml of 125I-iothalamate,
and at 30-min intervals starting 3 h after administration.
eGFR were calculated according to the 4-variable Modi-
ﬁcation of Diet in Renal Disease (MDRD), Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI),
and Cockcroft-Gault (CG) formulas (7–9), as previously
described (4). The percent changes in iGFR and eGFR were
calculated for all patients after renal stenting. For compari-
son of iGFR and eGFR, patients were included if iGFR
were available before and after renal stenting, and patients
were on stable doses of antihypertensive and diureticmedications between serum creatinine (SCr) and iGFR
measurements. SCr was measured by the Beaumont Refer-
ence Laboratory using the modiﬁed Jaffé reaction indirectly
traceable to isotope dilution mass spectrometry (Roche
Modular Instruments, Roche Diagnostics, Indianapolis,
Indiana) as previously described (4). This study was
approved by the Human Investigations Committee of
Beaumont Health System.
Statistical methods. iGFR and eGFR were compared with
each other before and after stenting using paired Student
t tests, and the percent changes in iGFR after stenting were
compared with percent changes in eGFR. Compared with
baseline, iGFR after stenting was considered stable if the
iGFR increased or decreased by <20%, increased if iGFR
increased by 20%, and decreased if iGFR decreased by
20%. Pearson correlation coefﬁcients were used to study
the correlation between percent changes in iGFR and eGFR
after stenting. Because a 20% change in eGFR has been used
as a renal endpoint in randomized trials of renal revascu-
larization (10,11), a k-statistic was generated to assess the
degree of agreement between 20% changes in iGFR and
eGFR. The sensitivity, speciﬁcity, and positive and negative
Figure 1. Correlation of eGFR and iGFR
(A) Percent change in iGFR and MDRD. (B) Percent change in CKD-EPI. CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration; eGFR ¼ estimated glomerular
ﬁltration rate; iGFR ¼ 125I-iothalamate glomerular ﬁltration rate; MDRD ¼ Modiﬁcation of Diet in Renal Disease.
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545predictive values of eGFR were determined for identifying a
20% increase and a20% decrease in iGFR after stenting.
Receiver-operating characteristic curves were constructed,
and the area under the curve (AUC) was calculated for
identifying a 20% increase or decrease in iGFR. The
reliability of the estimates was characterized as excellent
(AUC 0.9), good (AUC ¼ 0.8 to 0.89), fair (AUC ¼ 0.7
to 0.79), and poor (AUC < 0.7). Categorical variables are
reported as frequencies. Continuous variables, including
SCr, age, and time, are reported as mean  SD, and all
others are reported as median (25th to 75th percentiles).
Bland-Altman analysis was performed using Microsoft
Excel Analyze-IT 210 (Microsoft Corporation, Redmond,Washington); other analyses were performed using SAS
for Windows (version 9.2, Cary, North Carolina).Results
Study population. Between 1998 and 2007, 81 RAS pa-
tients underwent renal artery stenting and had iGFR and
SCr measured before and after renal stenting. Three patients
had repeat intervention more than 1 year following initial
intervention and were considered as separate entries, pro-
ducing a total of 84 patients (Table 1). GFR was performed
87  122 days before stenting and 180  171 days after
Figure 2. Bland-Altman Plots Assessing Precision and Bias of eGFR Compared With iGFR
(A) Percent change in iGFR and MDRD. (B) Percent change in iGFR and CKD-EPI. (C) Percent change in iGFR and CG. Abbreviations as in Figure 1.
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546stenting. SCr was performed within 2 weeks of iGFR in
81% of patients.
Baseline renal function. Before revascularization, the mea-
sured iGFR was 54.0  19.9 ml/min/1.73 m2. BaselineeGFR were 51.4  20.2 ml/min/1.73 m2 using MDRD,
49.9  19.8 ml/min/1.73 m2 using CKD-EPI, and 52.1 
18.4 ml/min/1.73 m2 using CG. At baseline, iGFR was
<60 ml/min/1.73 m2 in 58 (69.1%) measurements,
Table 3. Frequency of 20% Changes in GFR After Renal Artery Stenting
GFR Method
20% Increase*
(Percent of Patients)
20% Decrease*
(Percent of Patients)
iGFR 22.6 14.3
MDRD 16.7 17.9
CKD-EPI 16.7 19.1
CG 10.3 15.4
*Degree of agreement was poor between iGFR and eGFR to detect 20% increase (k ¼ 0.29 for
MDRD andCKD-EPI, 0.23 for CG) or decrease (k¼ 0.52 for MDRD, 0.49 for CKD-EPI, and 0.26 for CG).
eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in Table 1.
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547consistent with CKD. At baseline, eGFR was <60 ml/min/
1.73 m2 in 65.5% by MDRD, 67.9% by CKD-EPI, and
66.7% by CG. Baseline eGFR incorrectly diagnosed CKD in
2.4% to 8.3% patients and missed CKD in 9.5% to 11.9%.
Change in renal function after stenting. iGFRbefore (54.0
19.9ml/min/1.73m2) and after (56.2 24.3ml/min/1.73m2)
stenting were similar (Table 2). After revascularization,
iGFR increased in 22.6%, decreased in 14.3%, and re-
mained stable in 63.1% of patients.
There was no difference in eGFR before and after
stenting for MDRD (51.4  20.2 ml/min/1.73 m2 vs.
51.6  23.7 ml/min/1.73 m2, p ¼ NS), CKD-EPI (49.4
 19.8 ml/min/1.73 m2 vs. 48.9  21.3 ml/min/1.73 m2,
p ¼ NS), or CG (63.2  20.7 ml/min/1.73 m2 vs. 64.2 
13.4 ml/min/1.73 m2, p ¼ NS) (Table 2). Whereas iGFR
identiﬁed any increase in GFR after revascularization in
57.1% of patients, only 40.5% of patients had any increase
in eGFR by MDRD, 40.5% by CKD-EPI, and 53.9%
by CG. Correlations between percent changes in iGFR
and eGFR were poor: MDRD r2 ¼ 0.32 (p ¼ 0.0034);
CKD-EPI r2 ¼ 0.31 (p¼ 0.0037); CG r2 ¼ 0.32 (p ¼
0.05) (Fig. 1). The median differences (biases) between theTable 4. Diagnostic Performance of eGFR
20% Decrease in iGFR
Sensitivity Speciﬁcity PPV NPV AUC
MDRD 67 90 55 94 0.72 (0.40–1.0)
CKD-EPI 67 89 50 94 0.71 (0.37–1.0)
CG 40 88 33 91 0.69 (0.36, 1.0)
20% Increase in iGFR
Sensitivity Speciﬁcity PPV NPV lAUC
MDRD 37 89 50 83 0.75 (0.58–0.93)
CKD-EPI 37 89 50 83 0.77 (0.59–0.94)
CG 25 94 50 83 0.75 (0.58–0.92)
Values are % or AUC (95% conﬁdence interval).
AUC ¼ area under the receiver-operating characteristic curve; NPV ¼ negative predictive
value; PPV ¼ positive predictive value; other abbreviations as in Tables 1 and 3.estimates and iGFR were 3.7  3.2, 4.4  3.2, and 3.8 
2.7 ml/min/1.73 m2 for MDRD, CKD-EPI, and CG,
respectively. The precision of GFR estimates demonstrated
interquartile ranges of 11.2 to 19.1, 10.8 to 19.6, and
11.0 to 21.2 ml/min/1.73 m2 for MDRD, CKD-EPI,
and CG, respectively (Fig. 2). After revascularization, the
direction of change in eGFR was discordant with the di-
rection of change in iGFR in 38.1% of MDRD, 38.1% of
CKD-EPI, and 46.2% of CG.
A 20% increase was identiﬁed by iGFR in 22.6% of
patients, by MDRD in 16.7%, by CKD-EPI in 16.7%,
and by CG in 10.3% (Table 3). The degree of agreement
to detect 20% increase in iGFR was poor for MDRD
(k ¼ 0.29, 95% conﬁdence interval [CI]: 0.05 to 0.53),
CKD-EPI (k ¼ 0.29, 95% CI: 0.05 to 0.53), and CG
(k ¼ 0.23, 95% CI: 0.14 to 0.59). A 20% decrease
was identiﬁed by iGFR in 14.3% of patients, by MDRD
in 17.9%, by CKD-EPI in 19.1%, and by CG in 15.4%
(Table 3). These data suggest that serial eGFR consistently
underestimate the frequency of improvement in iGFR, and
overestimate the frequency of decline in iGFR. The degree
of agreement to detect 20% decrease in iGFR was poor
for MDRD (k ¼ 0.52, 95% CI: 0.27 to 0.76), CKD-EPI
(k ¼ 0.49, 95% CI: 0.24 to 0.74), and CG (k ¼ 0.26, 95%
CI: 014. to 0.66).
Overall, GFR estimates were characterized by poor
sensitivity, modest speciﬁcity, and poor reliability for iden-
tifying 20% increase (AUC: 0.75 to 0.77) and 20%
decrease (AUC: 0.69 to 0.72) in iGFR (Table 4, Fig. 3).
Discussion
Epidemiological studies suggest a strong association be-
tween cardiovascular mortality and stages of CKD when
classiﬁed by eGFR (12). Use of eGFR has also led to
recognition of earlier stages of CKD in elderly patients, and
may result in less drug toxicity when drug dosages are
adjusted for eGFR. However, eGFR are less reliable at
higher levels of measured GFR (13), and may misclassify the
stage of CKD in 35% of patients (14). Although eGFR is
usually calculated using equations based on SCr, several
studies suggest that eGFR equations using serum cystatin-C
(alone or in combination with SCr) may be more accurate
(15,16). However, eGFR equations using cystatin-C have
not been validated for assessment of serial GFR, and cys-
tatin-C was not measured in our study.
Patients with RAS may have a combination of intrinsic
kidney disease and reduction in GFR and renal blood
ﬂow (17). Randomized trials of medical therapy versus renal
artery stenting failed to demonstrate any beneﬁt of renal
revascularization, frequently relying on 20% changes in
eGFR as the primary renal endpoint (10,11). However, a
more recent study of RAS patients demonstrated that
eGFR are not valid for assessment of serial renal function
Figure 3. ROC Curves for eGFR and iGFR
(A) Decrease in iGFR by 20%. AUC ¼ 0.72 (MDRD), 0.71 (CKD-EPI), and 0.69
(CG). (B) Increase in iGFR by 20%. AUC ¼ 0.75 (MDRD, CG) and 0.77 (CKD-
EPI). AUC ¼ area under the curve; ROC ¼ receiver-operating characteristic;
other abbreviations as in Figure 1.
Crimmins et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 5 , 2 0 1 4
GFR After Renal Artery Stenting M A Y 2 0 1 4 : 5 4 3 – 9
548(4). In that study, the CKD stage was incorrectly classiﬁed
by eGFR in nearly one-third of patients; there were poor
correlations between 20% changes in eGFR and iGFR;
and the direction of change (increase or decrease in GFR)
was discordant in up to 40% of patients.
The present study extends the ﬁndings of our previous
study (4) to the subset of RAS patients who undergo renal
artery stenting. eGFR are unreliable for detecting
20% changes in iGFR and for identifying the direction
and magnitude of change in iGFR after renal stenting.
Furthermore, compared with iGFR, eGFR underestimates
improvement and overestimates deterioration in serial re-
nal function after stenting. Compared with baseline,
the percent changes in iGFR and eGFR and the degree
of agreement between iGFR and eGFR after stenting
are poor.
Study limitations. The present study was designed to
evaluate the validity of eGFR for assessing changes inmeasured GFR after renal stenting. The study was not
designed to compare medical therapy with revascularization;
assess important cardiovascular endpoints such as death,
stroke, myocardial infarction, and heart failure; or evaluate
the impact of renal revascularization on blood pressure or
renal function. Other measures of eGFR were not evaluated
because the frequency was too low (doubling of SCr) or data
were not collected (serum cystatin-C).
Conclusions
In patients with RAS, eGFR are unreliable for detecting
20% changes in measured GFR after renal stenting. eGFR
are invalid endpoints for assessing serial GFR in patients
with RAS, and should be abandoned as major endpoints in
trials of renal revascularization.
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